Receive a weekly summary and discussion of the top papers of the week by leading researchers in the field.

In Proceedings. IEEE International Conference on Bioinformatics and Biomedicine

Breast cancer is the most prevalent and among the most deadly cancers in females. Patients with breast cancer have highly variable survival rates, indicating a need to identify prognostic biomarkers. By integrating multi-omics data (e.g., gene expression, DNA methylation, miRNA expression, and copy number variations (CNVs)), it is likely to improve the accuracy of patient survival predictions compared to prediction using single modality data. Therefore, we propose to develop a machine learning pipeline using decision-level integration of multi-omics tumor data from The Cancer Genome Atlas (TCGA) to predict the overall survival of breast cancer patients. With multi-omics data consisting of gene expression, methylation, miRNA expression, and CNVs, the top performing model predicted survival with an accuracy of 85% and area under the curve (AUC) of 87%. Furthermore, the model was able to identify which modalities best contributed to prediction performance, identifying methylation, miRNA, and gene expression as the best integrated classification combination. Our method not only recapitulated several breast cancer-specific prognostic biomarkers that were previously reported in the literature but also yielded several novel biomarkers. Further analysis of these biomarkers could lend insight into the molecular mechanisms that lead to poor survival.

Mitchel Jonathan, Chatlin Kevin, Tong Li, Wang May D


Biomarker Identification, Breast Cancer, Decision-Level Integration, Multi-Omics, Overall Survival